ISSN 1662-4009 (online)

ey0016.3-13 | Graves’ Disease | ESPEYB16

3.13. Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial

M Cole , AM Hynes , D Howel , L Hall , M Abinun , A Allahabadia , T Barrett , K Boelaert , AJ Drake , P Dimitri , J Kirk , N Zammitt , S Pearce , T Cheetham

To read the full abstract: BMJ Open. 2019;9:e024705.This protocol paper describes an innovative phase II trial to study the effect of a single low dose of adjuvant rituximab (a chimeric anti-B-cell monoclonal antibody targeting the surface molecule CD20) compared to classical carbimazole therapy in adolescents and young adults with Graves’ disease. Carbimazole treatment will be stop...

ey0016.5-17 | Basic Science - Bone | ESPEYB16

5.17. Coupling of bone resorption and formation by RANKL reverse signalling

Y Ikebuchi , S Aoki , M Honma , M Hayashi , Y Sugamori , M Khan , Y Kariya , G Kato , Y Tabata , JM Penninger , N Udagawa , K Aoki , H Suzuki

Abstract: Nature. 2018 Sep;561(7722):195–200.In brief: This study used various cell-based methods and animal models to investigate the RANK-RANKL signaling pathway in bone homeostasis. The authors show for the first time, that reverse signaling exists from osteoclast to osteoblast and that vesicular RANK, secreted by the osteoclast, relays information to the osteoblast...

ey0016.5-19 | Basic Science - Mineral Metabolism | ESPEYB16

5.19. Eldecalcitol causes FGF23 resistance for Pi reabsorption and improves rachitic bone phenotypes in the male Hyp mouse

I Kaneko , H Segawa , K Ikuta , A Hanazaki , T Fujii , S Tatsumi , S Kido , T Hasegawa , N Amizuka , H Saito , KI Miyamoto

Abstract: Endocrinology, Volume 159, Issue 7, July 2018, Pages 2741–2758In brief: Eldecalcitol, a long acting active vitamin D3 analogue with lower affinity for vitamin D receptor and resistance to inactivation by vitamin D 24-hydroxylase, causes FGF23 resistance. This leads to complete restoration of renal phosphate transport and NaPi-2a protein levels and improves ra...

ey0016.6-1 | DSD New Paradigm | ESPEYB16

6.1. Oestrogen versus androgen in hormone-replacement therapy for complete androgen insensitivity syndrome: a multicentre, randomised, double-dummy, double-blind crossover trial

W Birnbaum , L Marshall , R Werner , A Kulle , PM Holterhus , K Rall , B Kohler , A Richter-Unruh , MF Hartmann , SA Wudy , MK Auer , A Lux , S Kropf , O Hiort

Lancet Diabetes Endocrinol. 2018 Oct;6(10):771–780.doi: 10.1016/S2213-8587(18)30197-9.For the first time a prospective randomized treatment study has been performed for individuals with a DSD. This national multi-center, double-blind, randomized, cross-over trial compared estrogen therapy to androgen replacement in complete androgen insensitivity syndrome ...

ey0016.7-4 | Genetics of Puberty | ESPEYB16

7.4. HS6ST1 insufficiency causes self-limited delayed puberty in contrast with other GnRH deficiency genes

SR Howard , R Oleari , A Poliandri , V Chantzara , A Fantin , G Ruiz-Babot , LA Metherell , CP Cabrera , MR Barnes , K Wehkalampi , L Guasti , C Ruhrberg , A Cariboni , L Dunkel

To read the full abstract: J Clin Endocrinol Metab. 2018 Sep 1;103(9):3420–3429.This whole-exome study in 67 probands and 93 relatives from a large cohort of familial delayed puberty identifies a new heterozygous HS6ST1 mutation as a novel cause of delayed puberty.The underlying pathophysiology of early and delayed puberty remains unexplained in most ...

ey0016.8-14 | New Hope | ESPEYB16

8.14. A report on state-wide implementation of newborn screening for X-linked adrenoleukodystrophy

K Wiens , SA Berry , H Choi , A Gaviglio , A Gupta , A Hietala , D Kenney-Jung , T Lund , W Miller , EI Pierpont , G Raymond , H Winslow , HA Zierhut , PJ Orchard

To read the full abstract: Am J Med Genet A. 2019; 179(7):1205–1213.X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder, with an estimated incidence in the USA of ~1:17,000 all births (male and female) and 1:21,000 male births. X-ALD is caused by mutations in the X chromosome gene ABCD1, which encodes the peroxisomal membrane protein, ATP-bin...

ey0016.13-8 | Endocrinology: Disorders of Sexual Development | ESPEYB16

13.8. Malaysian females with congenital adrenal hyperplasia: surgical outcomes and attitudes

AA Zainuddin , SR Grover , CH Soon , AG Nur Azurah , ZA Mahdy , LL Wu , R Rasat , F Harun , WY Chia , K Shamsuddin

Front Pediatr 2019, 7:144. DOI: 10.3389/fped.2019.00144• The outcomes of feminizing genitoplasty of 46,XX individuals with CAH were reviewed in this cross-sectional study.• The study highlights the importance of cultural sensitivities, access to medical treatment and timing of the diagnosis on attitudes toward feminizing genitoplasty in Malaysia.<p cl...

ey0016.14-11 | (1) | ESPEYB16

14.11. Neonatal selection by Toll-like receptor 5 influences long-term gut microbiota composition

M Fulde , F Sommer , B Chassaing , K van Vorst , A Dupont , M Hensel , M Basic , R Klopfleisch , P Rosenstiel , A Bleich , F Backhed , AT Gewirtz , MW Hornef

To read the full abstract: Nature 2018;560:489–493.This paper reports competitive gut colonization experiments in mice. Compared to adult mice, neonatal mice showed much higher expression of the flagellin receptor Tlr5 in their intestinal epithelial cells, and exposure to this protein during the first 2 weeks of life, before weaning, was crucial in determining lifelong...

ey0016.14-18 | (1) | ESPEYB16

14.18. Darolutamide in nonmetastatic, castration-resistant prostate cancer

K Fizazi , N Shore , TL Tammela , A Ulys , E Vjaters , S Polyakov , M Jievaltas , M Luz , B Alekseev , I Kuss , C Kappeler , A Snapir , T Sarapohja , MR Smith , A Investigators

To read the full abstract: N Engl J Med 2019;380:1235–1246This paper reports a randomized, double-blind, placebo-controlled, phase 3 trial of darolutamide, a novel oral androgen-receptor antagonist, in 1509 men with non-metastatic, castration-resistant prostate cancer. Median metastasis-free survival was significantly longer with darolutamide (40.4 months) than placebo (18.4 ...

ey0015.1-8 | New mouse model | ESPEYB15

1.8 Hypothalamic loss of Snord116 recapitulates the hyperphagia of Prader-Willi syndrome

J Polex-Wolf , BY Lam , R Larder , J Tadross , D Rimmington , F Bosch , VJ Cenzano , E Cenzano , MK Ma , K Rainbow , AP Coll , S O'Rahilly , GS Yeo

To read the full abstract: J Clin Invest 2018;128:960-969Mouse models for PWS are urgently needed to facilitate drug development for treatment of hyperphagia and obesity in PWS patients. Here, the authors set out to create a mouse model that better recapitulates human PWS; they chose Snord116 as the target. Snord116 comprises a cluster of noncoding RNAs (ncRNAs) on paternal chromosome 15q11.2. Deletio...